JO3753B1 - قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه - Google Patents
قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منهInfo
- Publication number
- JO3753B1 JO3753B1 JOP/2012/0301A JOP20120301A JO3753B1 JO 3753 B1 JO3753 B1 JO 3753B1 JO P20120301 A JOP20120301 A JO P20120301A JO 3753 B1 JO3753 B1 JO 3753B1
- Authority
- JO
- Jordan
- Prior art keywords
- quinolin
- thiophen
- piperazin
- benzo
- butoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
يتعلق ذلك الاختراع بقرص يتضمن، كمكون أساسي نشط، 7-<span dir="LTR">]</span>4-(4-بنزو<span dir="LTR"> [b] </span>ثيوفين-4-يل-بيبرازين-1-يل)بيوتوكسي<span dir="LTR">[</span>-1<span dir="LTR">H</span>-كينولين-2- أون أو ملح منه، يكون له قابلية تقتت ممتازة، استقرار أثناء التخزين و الاستقرار الضوئي. <span dir="RTL">يحتوي القرص الخاص بالاختراع الحالي على 7-</span>]<span dir="RTL">4-(4- بنزو </span>[b] <span dir="RTL">ثيوفين-4-يل- بيبرازين-1-يل) بيوتوكسي</span>[<span dir="RTL">-1</span>H<span dir="RTL">-كينولين-2- أون أو ملح منه كمكون أساسي نش، و يحتوي أيضا على عامل تغطية تتضمن لاكتوز، نشا الذرة، بلورة سيلولوز دقيقة و سواغات مشابهة؛ هيدروكسي بروبيل سيلولوز منخفض الاستبدال، كروسكارميلوز صوديوم، صوديوم كربوكسيل ميثيل نشا و مواد مفتتة مشابهة؛ هيدروكسي بروبيل سيلولوز و مواد رابطو مشابهة؛ ميلوز فائق؛تلك؛ أكسيد تيتانيوم؛ مواد ملونة؛ و ما شابه ذلك.</span>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011227057 | 2011-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3753B1 true JO3753B1 (ar) | 2021-01-31 |
Family
ID=48081918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2012/0301A JO3753B1 (ar) | 2011-10-14 | 2012-10-04 | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
Country Status (32)
Country | Link |
---|---|
US (7) | US20140234417A1 (ar) |
EP (1) | EP2767285B1 (ar) |
JP (2) | JP6084161B2 (ar) |
KR (1) | KR102072371B1 (ar) |
CN (2) | CN107397730A (ar) |
AP (1) | AP2014007564A0 (ar) |
AR (1) | AR088319A1 (ar) |
AU (1) | AU2012321723C1 (ar) |
BR (1) | BR112014008603A2 (ar) |
CA (1) | CA2851588C (ar) |
CL (1) | CL2014000909A1 (ar) |
CO (1) | CO6950480A2 (ar) |
CY (1) | CY1122460T1 (ar) |
DK (1) | DK2767285T3 (ar) |
EA (1) | EA032930B1 (ar) |
ES (1) | ES2762479T3 (ar) |
HR (1) | HRP20200037T1 (ar) |
HU (1) | HUE047493T2 (ar) |
IL (1) | IL231513B (ar) |
IN (1) | IN2014DN02055A (ar) |
JO (1) | JO3753B1 (ar) |
LT (1) | LT2767285T (ar) |
MX (1) | MX2014004135A (ar) |
MY (1) | MY173370A (ar) |
PL (1) | PL2767285T3 (ar) |
PT (1) | PT2767285T (ar) |
SG (2) | SG2014013783A (ar) |
SI (1) | SI2767285T1 (ar) |
TW (1) | TWI634908B (ar) |
UA (1) | UA114411C2 (ar) |
WO (1) | WO2013054872A1 (ar) |
ZA (1) | ZA201402333B (ar) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
JP5936732B1 (ja) * | 2015-03-05 | 2016-06-22 | 日本カラコン合同会社 | フィルムコーティング組成物 |
CN105106142B (zh) * | 2015-09-22 | 2018-05-22 | 成都欣捷高新技术开发有限公司 | 一种含有依匹哌唑的冻干口服制剂及其制备方法 |
CN106994119A (zh) * | 2016-01-22 | 2017-08-01 | 浙江华海药业股份有限公司 | 含有依匹哌唑或其盐的口腔崩解片及其制备方法 |
CN107530348B (zh) * | 2016-02-19 | 2020-10-20 | 江苏恒瑞医药股份有限公司 | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 |
CN109414051A (zh) * | 2016-06-28 | 2019-03-01 | 株式会社日本抗菌总和研究所 | 赋形剂和片剂 |
TWI728156B (zh) * | 2016-07-27 | 2021-05-21 | 日商日本臟器製藥股份有限公司 | 含有胺甲蝶呤之膜衣錠 |
EP3500249A1 (en) | 2016-08-16 | 2019-06-26 | Hexal Aktiengesellschaft | Pharmaceutical compositions of a benzothiophene compound |
US11123300B2 (en) | 2016-08-16 | 2021-09-21 | Hexal Ag | Immediate release tablet of a benzothiophene compound |
CN106496206A (zh) * | 2016-08-31 | 2017-03-15 | 安徽省润生医药股份有限公司 | 一种依匹哌唑新的制备方法 |
MX2019010003A (es) * | 2017-02-23 | 2019-12-16 | Boehringer Ingelheim Int | Nuevo uso medico del compuesto iii. |
JP7166754B2 (ja) * | 2017-11-22 | 2022-11-08 | 沢井製薬株式会社 | ダサチニブ無水物含有製剤 |
EP3501506B1 (en) | 2017-12-19 | 2019-10-09 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
EP3545950A1 (en) | 2018-03-26 | 2019-10-02 | Adamed sp. z o.o. | Pharmaceutical composition comprising brexpiprazole |
JPWO2021029020A1 (ar) * | 2019-08-13 | 2021-02-18 | ||
CN112168794A (zh) * | 2020-10-27 | 2021-01-05 | 浙江诺得药业有限公司 | 一种布瑞哌唑片的制备方法 |
WO2022218358A1 (zh) * | 2021-04-13 | 2022-10-20 | 上海博志研新药物技术有限公司 | 一种布瑞哌唑物口腔薄膜剂、其制备方法及应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562375B1 (en) * | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
US20030153617A1 (en) * | 2001-12-18 | 2003-08-14 | Dalen Frans Van | Simvastatin dosage forms |
JP4584706B2 (ja) * | 2002-05-03 | 2010-11-24 | イスラエル インスティチュート フォー バイオロジカル リサーチ | 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物 |
OA13050A (en) | 2003-04-29 | 2006-11-10 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. |
BRPI0411378A (pt) * | 2003-06-09 | 2006-08-01 | Dow Global Technologies Inc | composição polimerizável de duas partes, método de polimerização, método para ligar dois ou mais componentes entre si, método para modificar a superfìcie de um polìmero de energia superficial baixa, método para revestir um substrato, composição de revestimento, laminado e composição polimerizável de uma parte |
JP2006061067A (ja) * | 2004-08-26 | 2006-03-09 | Asahi Kasei Life & Living Corp | 酸素インジケーター |
GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
ES2526415T3 (es) | 2005-03-17 | 2015-01-12 | Synthon B.V. | Comprimidos farmacéuticos de aripiprazol cristalino de tipo II |
TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
DK1808164T3 (da) | 2006-01-05 | 2009-04-20 | Teva Pharma | Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol |
JP4806595B2 (ja) * | 2006-07-05 | 2011-11-02 | 富士フイルム株式会社 | 固体撮像素子駆動装置及びデジタルカメラ |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
EP2132173B1 (en) * | 2007-02-26 | 2015-10-07 | Merck Sharp & Dohme Corp. | Formulations for cathepsin k inhibitors |
JP5432720B2 (ja) * | 2007-03-13 | 2014-03-05 | 武田薬品工業株式会社 | 2−[[6−[(3r)−3−アミノ−1−ピペリジニル]−3,4−ジヒドロ−3−メチル−2,4−ジオキソ−1(2h)−ピリミジニル]メチル]−4−フルオロベンゾニトリルを含む固形製剤 |
WO2008140051A1 (ja) * | 2007-05-11 | 2008-11-20 | Santen Pharmaceutical Co., Ltd. | 非麦角系の選択的d2受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤 |
KR20100099113A (ko) * | 2007-10-12 | 2010-09-10 | 아스트라제네카 아베 | 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물 |
JP5463564B2 (ja) * | 2009-05-22 | 2014-04-09 | 国立大学法人信州大学 | 耐熱性及び耐塩性セルラーゼ製剤 |
TR201000948A1 (tr) | 2010-02-09 | 2011-08-22 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Aripiprazol formülasyonları. |
JOP20120083B1 (ar) | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns |
CA2832022C (en) | 2011-04-06 | 2019-01-08 | Biovaxim Limited | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
-
2012
- 2012-10-04 JO JOP/2012/0301A patent/JO3753B1/ar active
- 2012-10-09 TW TW101137267A patent/TWI634908B/zh active
- 2012-10-12 SI SI201231718T patent/SI2767285T1/sl unknown
- 2012-10-12 AR ARP120103801A patent/AR088319A1/es not_active Application Discontinuation
- 2012-10-12 ES ES12840025T patent/ES2762479T3/es active Active
- 2012-10-12 US US14/351,325 patent/US20140234417A1/en not_active Abandoned
- 2012-10-12 UA UAA201405029A patent/UA114411C2/uk unknown
- 2012-10-12 SG SG2014013783A patent/SG2014013783A/en unknown
- 2012-10-12 CN CN201710266863.7A patent/CN107397730A/zh active Pending
- 2012-10-12 KR KR1020147010656A patent/KR102072371B1/ko active IP Right Grant
- 2012-10-12 HU HUE12840025A patent/HUE047493T2/hu unknown
- 2012-10-12 WO PCT/JP2012/076415 patent/WO2013054872A1/ja active Application Filing
- 2012-10-12 CN CN201280050586.1A patent/CN103889425B/zh active Active
- 2012-10-12 AU AU2012321723A patent/AU2012321723C1/en active Active
- 2012-10-12 MX MX2014004135A patent/MX2014004135A/es active IP Right Grant
- 2012-10-12 PT PT128400256T patent/PT2767285T/pt unknown
- 2012-10-12 JP JP2013538582A patent/JP6084161B2/ja active Active
- 2012-10-12 PL PL12840025T patent/PL2767285T3/pl unknown
- 2012-10-12 CA CA2851588A patent/CA2851588C/en active Active
- 2012-10-12 EP EP12840025.6A patent/EP2767285B1/en active Active
- 2012-10-12 AP AP2014007564A patent/AP2014007564A0/xx unknown
- 2012-10-12 EA EA201490783A patent/EA032930B1/ru active Protection Beyond IP Right Term
- 2012-10-12 LT LTEP12840025.6T patent/LT2767285T/lt unknown
- 2012-10-12 SG SG10201608412SA patent/SG10201608412SA/en unknown
- 2012-10-12 BR BR112014008603A patent/BR112014008603A2/pt not_active Application Discontinuation
- 2012-10-12 MY MYPI2014700632A patent/MY173370A/en unknown
- 2012-10-12 DK DK12840025.6T patent/DK2767285T3/da active
-
2014
- 2014-03-13 IL IL231513A patent/IL231513B/en active IP Right Grant
- 2014-03-19 IN IN2055DEN2014 patent/IN2014DN02055A/en unknown
- 2014-03-28 ZA ZA2014/02333A patent/ZA201402333B/en unknown
- 2014-04-10 CL CL2014000909A patent/CL2014000909A1/es unknown
- 2014-05-07 CO CO14098041A patent/CO6950480A2/es unknown
-
2016
- 2016-02-09 US US15/019,874 patent/US20160158227A1/en not_active Abandoned
-
2017
- 2017-01-20 JP JP2017008854A patent/JP2017088610A/ja active Pending
- 2017-02-27 US US15/444,113 patent/US20170165258A1/en not_active Abandoned
- 2017-09-22 US US15/713,427 patent/US10307419B2/en active Active
-
2019
- 2019-04-12 US US16/383,488 patent/US20190240215A1/en not_active Abandoned
-
2020
- 2020-01-08 CY CY20201100009T patent/CY1122460T1/el unknown
- 2020-01-09 HR HRP20200037TT patent/HRP20200037T1/hr unknown
- 2020-10-01 US US17/061,394 patent/US20210023078A1/en not_active Abandoned
-
2022
- 2022-03-07 US US17/653,838 patent/US20220331311A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3753B1 (ar) | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه | |
PH12016501310A1 (en) | Pharmaceutical compositions comprising azd9291 | |
WO2011093672A3 (en) | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | |
PH12014501504A1 (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | |
WO2011093684A3 (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | |
MY197785A (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
TN2013000257A1 (en) | Immunosuppressant formulations | |
NZ630255A (en) | Injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof | |
MY162392A (en) | Enteric tablet | |
PH12019501873A1 (en) | Pharmaceutical composition | |
WO2011037976A3 (en) | Pramipexole pharmaceutical formulations | |
PL2647637T3 (pl) | Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf | |
NZ708959A (en) | Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same | |
JP2016108327A5 (ar) | ||
MX2012001691A (es) | Composiciones de linaclotida que se desintegran oralmente. | |
GEP20156332B (en) | Pyrazoles as crth2 antagonists | |
PH12019501288A1 (en) | Novel preparation containing benzimidazole derivative | |
TN2014000177A1 (en) | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation | |
WO2010104485A3 (en) | Valsartan formulations | |
PH12019501260A1 (en) | A fast disintegrating pharmaceutical composition | |
TH168085A (th) | ยาเตรียมของการรวมกันทางเภสัชกรรมที่ประกอบด้วยตัวยับยั้งเอนไซม์เอชเอ็มจี-โคเอ รีดัคเตส และ ตัวยับยั้งการดูดซึมคลอเลสเตอรอล | |
TH168085B (th) | ยาเตรียมของการรวมกันทางเภสัชกรรมที่ประกอบด้วยตัวยับยั้งเอนไซม์เอชเอ็มจี-โคเอ รีดัคเตส และ ตัวยับยั้งการดูดซึมคลอเลสเตอรอล | |
UA91283U (uk) | Фармацевтичний продукт, що має виражену антигестагенну дію | |
UA47107U (en) | Drug formulation in tablet form possessing mucolytic and antihistamine properties |